Turning Point Therapeutics (NASDAQ:TPTX) CFO Yi Larson Acquires 2,222 Shares

Turning Point Therapeutics (NASDAQ:TPTX) CFO Yi Larson acquired 2,222 shares of the stock in a transaction dated Tuesday, September 10th. The stock was bought at an average cost of $45.00 per share, with a total value of $99,990.00.

Shares of Turning Point Therapeutics stock opened at $44.74 on Friday. Turning Point Therapeutics has a 52 week low of $24.21 and a 52 week high of $58.56. The business has a 50 day moving average of $45.11. The company has a debt-to-equity ratio of 0.01, a current ratio of 32.35 and a quick ratio of 32.35.

Turning Point Therapeutics (NASDAQ:TPTX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.05). On average, equities research analysts predict that Turning Point Therapeutics will post -2.94 earnings per share for the current fiscal year.

Several analysts have recently commented on the company. Wedbush assumed coverage on Turning Point Therapeutics in a research note on Monday. They issued an “outperform” rating and a $63.00 price objective for the company. Guggenheim assumed coverage on Turning Point Therapeutics in a research note on Wednesday, July 24th. They issued a “buy” rating and a $58.00 price objective for the company. Zacks Investment Research reissued a “hold” rating on shares of Turning Point Therapeutics in a research note on Saturday, September 7th. Wells Fargo & Co increased their price objective on Turning Point Therapeutics from $53.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. Finally, Canaccord Genuity increased their price objective on Turning Point Therapeutics from $53.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Turning Point Therapeutics has a consensus rating of “Buy” and an average price target of $52.63.

Several hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC bought a new position in shares of Turning Point Therapeutics in the second quarter valued at approximately $25,000. Wells Fargo & Company MN bought a new position in shares of Turning Point Therapeutics in the second quarter valued at approximately $72,000. JPMorgan Chase & Co. bought a new position in shares of Turning Point Therapeutics in the second quarter valued at approximately $71,000. Cubist Systematic Strategies LLC bought a new position in shares of Turning Point Therapeutics in the second quarter valued at approximately $90,000. Finally, Alpine Woods Capital Investors LLC bought a new position in shares of Turning Point Therapeutics in the second quarter valued at approximately $204,000. 58.17% of the stock is owned by institutional investors.

About Turning Point Therapeutics

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Further Reading: Is the QQQ ETF safe?

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.